Clinicopathological features associated with CD44 and CD63 expression in breast cancer

Carlos A Castaneda ^1,2, Miluska Castillo ³, Joselyn Sanchez ³

⁰Faculty of Health Sciences, Universidad Cientifica del Sur, Lima 15067, Peru.

Ecancermedicalscience +

|

October 21, 2024

View abstract on PubMed

Summary

High CD44 expression in breast cancer correlates with aggressive traits and poorer survival, while CD63 expression is linked to favorable characteristics. This study in Peruvian women highlights potential biomarkers for breast cancer prognosis.

Area Of Science

Oncology
Molecular Biology
Biomarker Discovery

Background

CD44 is a cell-surface glycoprotein regulating cell division, adhesion, migration, and stem-like properties.
CD63 is a protein involved in the exocytosis process.

Purpose Of The Study

To investigate the association between CD44 and CD63 expression and breast cancer clinicopathological features.
To evaluate the relationship with tumor-infiltrating lymphocytes (TILs), PIK3CA mutation status, and patient survival.

Main Methods

Immunohistochemical staining for CD44 and CD63 was performed on 101 breast cancer tissue samples from Peruvian women.
Clinicopathological data, including tumor stage, grade, hormone receptor status, ki67, TILs, PIK3CA mutation, and survival, were analyzed.

Main Results

High CD44 expression (density and intensity) was significantly associated with younger age, triple-negative phenotype, and shorter survival.
High CD63 cell density was linked to estrogen receptor-positive status, Luminal-A subtype, low TIL levels, and lower CD44 intensity.
Factors associated with longer survival included earlier stages, lower ki67, ER-positive status, luminal phenotype, and recurrence.

Conclusions

CD44 expression is associated with aggressive clinicopathological features and reduced survival in this cohort.
CD63 expression is linked to more favorable prognostic indicators.
CD44 and CD63 may serve as potential prognostic biomarkers in breast cancer.

Keywords:

CD44 CD63 breast cancer tumor-infiltrating lymphocytes